Disclosure Of First-Time Adoption [Text Block]

Xbrane Biopharma - Filing #679209

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Disclosure of first-time adoption [text block]
Disclosure of comparative information prepared under previous GAAP [text block]
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity
171 335 SEK
1 273 999 SEK
6 683 SEK
10 121 SEK
1 428 530 SEK
424 888 SEK
885 827 SEK
6 166 SEK
10 322 SEK
1 294 227 SEK
713 313 SEK
1 134 276 SEK
431 741 SEK
5 165 SEK
5 614 SEK
Comprehensive income
388 373 SEK
388 172 SEK
201,000 SEK
0 SEK
0 SEK
SEK
167 356 SEK
172 513 SEK
5 157 SEK
SEK
Profit (loss)
388 172 SEK
388 172 SEK
172 513 SEK
172 513 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.